RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer
Public ClinicalTrials.gov record NCT05966194. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Study identification
- NCT ID
- NCT05966194
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EpicentRx, Inc.
- Industry
- Enrollment
- 216 participants
Conditions and interventions
Conditions
Interventions
- Cisplatin for injection 100 mg/m2 Drug
- Intensity Modulated Radiation Therapy (IMRT) Radiation
- RRx-001 Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 1, 2024
- Primary completion
- Jun 30, 2025
- Completion
- Sep 30, 2025
- Last update posted
- Nov 14, 2024
2024 – 2025
United States locations
- U.S. sites
- 14
- U.S. states
- 13
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | Recruiting |
| The University of Arizona Cancer Center | Tucson | Arizona | 85719 | Recruiting |
| Miami Cancer Institute | Miami | Florida | 33176 | Recruiting |
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | Recruiting |
| Parkview Cancer Institute | Fort Wayne | Indiana | 46845 | Recruiting |
| Willis Knighton Cancer Center | Shreveport | Louisiana | 71103 | Recruiting |
| Sandra and Malcolm Berman Cancer Institute | Baltimore | Maryland | 21204 | Recruiting |
| University of Michigan | Ann Arbor | Michigan | 48109 | Recruiting |
| Renown Regional Medical Center | Reno | Nevada | 89502 | Recruiting |
| East Carolina University School of Medicine | Greenville | North Carolina | 27834 | Recruiting |
| The Ohio State University James Cancer Hospital & Solove Research Institute | Columbus | Ohio | 43210 | Recruiting |
| Ballad Health | Johnson City | Tennessee | 37604 | Recruiting |
| University of Texas Southwestern Medical Center | Dallas | Texas | 75390 | Recruiting |
| University of Virginia | Charlottesville | Virginia | 22908 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05966194, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 14, 2024 · Synced May 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05966194 live on ClinicalTrials.gov.